Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Information (Tables)

Balance Sheet Information (Tables)

3 Months Ended

Mar. 31, 2022

Balance Sheet Information

Summary of cash and cash equivalents and restricted cash

A summary of cash and cash equivalents and restricted cash is as follows:


		March 31, 2022
		(unaudited)			December 31, 2021
Cash and Cash Equivalents		$	5,067,354		$	7,854,690
Restricted Cash, Non-current			45,000			45,000
Total Cash, Cash Equivalents and Restricted Cash		$	5,112,354		$	7,899,690

Schedule of accrued expenses


		March 31, 2022
		(unaudited)			December 31, 2021
Executive Severance		$	1,049,808		$	200,605
Payroll and Benefits			336,680			737,365
Professional Fees			384,452			194,425
Clinical Trials			61,994			168,785
Other			—			28,961
Total Accrued Expenses		$	1,832,934		$	1,330,141